2 results match your criteria: "AP-HP Central Paris University Hospitals[Affiliation]"
Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial.
Ann Oncol
August 2017
GINECO and Paris Descartes University, AP-HP Central Paris University Hospitals, Paris, France.
Background: In the open-label randomized phase III AURELIA trial, adding bevacizumab to chemotherapy for platinum-resistant ovarian cancer (PROC) significantly improved progression-free survival and response rate versus chemotherapy alone, but not overall survival (OS). We explored the effect of bevacizumab use after disease progression (PD) in patients randomized to chemotherapy alone.
Patients And Methods: In AURELIA, 361 women with PROC were randomized to chemotherapy alone or with bevacizumab.
Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial.
Ann Oncol
August 2016
GINECO and Paris Descartes University, AP-HP Central Paris University Hospitals, Paris, France.
Background: Data on CA-125 as a predictor of disease progression (PD) in ovarian cancer come predominantly from patients with platinum-sensitive disease receiving chemotherapy alone. We assessed concordance between CA-125-defined and RECIST-defined PD using data from the Gynecologic Cancer InterGroup (GCIG) randomized phase III AURELIA trial in platinum-resistant ovarian cancer (PROC).
Patients And Methods: Patients with PROC were randomized to receive single-agent chemotherapy with or without bevacizumab.